ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag brca1 immunology microbiology disease medicine

A needle drawing up fluid from an unlabeled vial.
Cancer Vaccination as a Promising New Treatment Against Tumors
Shelby Bradford, PhD | Mar 15, 2024 | 10+ min read
Vaccination has beaten back infections for more than a century. Now, it may be the next big step in battling cancer.
New Strategies in the Battle Against Infectious Diseases
New Strategies in the Battle Against Infectious Diseases
The Scientist Staff | Jan 8, 2024 | 2 min read
Learn how the latest research into viral and bacterial pathogens advances the prevention and treatment of infectious diseases. 
New Strategies to Discover Human Disease Genes
New Strategies to Discover Human Disease Genes
The Scientist | Oct 16, 2023 | 2 min read
Learn how researchers across health-related fields identify and characterize disease-causing genomic variants.
Illustration showing the upper part of a human body connected to a DNA helix
Unraveling the Mystery of Zombie Genes
Iris Kulbatski, PhD | Oct 31, 2023 | 6 min read
Digging into how and why some genes are resurrected after death sounds morbid, but it has practical applications. 
The Vaginal Microbiome is Finally Getting Recognized
Hannah Thomasy, PhD, Drug Discovery News | Sep 25, 2023 | 10+ min read
Vaginal dysbiosis has long been a taboo subject, but studying and optimizing the vaginal microbiome could be a game changer for women's health.
A silver tree showing roots and branches in a circle on a blue background.
Onward and Upward!
Kristie Nybo, PhD | Sep 8, 2023 | 9 min read
At The Scientist, we are strengthening our roots while reaching for the sky.
Interview with Stanley Falkow
John Dudley Miller | Apr 6, 2003 | 3 min read
Questions for Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University, who studies the genetic and molecular mechanisms by which bacteria become pathogenic. The Scientist: The Bush Administration's program calls for spending $1.75 billion annually over the next three years to fund bioterrorism research through the National Institute of Allergies and Infectious Diseases (NIAID) alone. That part of the plan directs the Institute to discover and produce al
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
RSV vaccine design concept art
RSV Vaccines That Work?
Rachael Moeller Gorman | Feb 16, 2023 | 10+ min read
Multiple candidates are in Phase 3 clinical trials for older adults and pregnant women, with some getting close to approval in the United States.
Illustration of HIV virus
Viral Protein Behind Chronic Inflammation in People with HIV: Study
Natalia Mesa, PhD | Dec 12, 2022 | 3 min read
The HIV protein Nef can cause long-term genetic changes that lead to hyperreactive immune cells, according to research in human cells and mice. 

Run a Search

ADVERTISEMENT